Site-directed delivery of VEGF-targeted liposomes into intracranial C6 glioma

Area of Science:

• Nanotechnology
• Oncology
• Neuroscience

Background:

• Conventional chemotherapy for aggressive central nervous system (CNS) tumors has limited efficacy.
• Targeted drug delivery systems are crucial for improving treatment outcomes in CNS cancers.
• Vascular Endothelial Growth Factor (VEGF) is often overexpressed in brain tumors, making it a viable therapeutic target.

Purpose of the Study:

• To develop and characterize pegylated liposomes conjugated with anti-VEGF monoclonal antibodies for targeted delivery to brain tumors.
• To evaluate the specificity, stability, and in vivo performance of these anti-VEGF liposomes.
• To assess the potential of targeted nanocarriers for enhancing anti-tumor substance delivery in CNS malignancies.

Main Methods:

• Synthesis and characterization of pegylated liposomes conjugated with anti-VEGF antibodies.
• Assessment of antibody immunochemical activity post-conjugation.
• In vitro and in vivo evaluation of liposome specificity and targeting in a rat C6 glioma model.
• Analysis of liposome accumulation and cellular uptake in tumor tissues.

Main Results:

• The developed nanoparticles exhibited narrow size distribution and high dispersion stability.
• Conjugated antibodies retained 70% of their initial immunochemical activity.
• Anti-VEGF liposomes demonstrated high specificity for VEGF-expressing tumor cells both in vitro and in vivo.
• Intravenous administration led to specific accumulation and engulfment of liposomes by glioma cells in the brain tumor.

Conclusions:

• Targeting molecules, such as anti-VEGF antibodies, significantly enhance the distribution and delivery efficiency of nanocontainers to brain tumors.
• Anti-VEGF liposomes represent a promising strategy for targeted therapy of CNS tumors overexpressing VEGF.
• This approach holds potential for improving the therapeutic efficacy of anti-tumor agents in challenging brain cancer models.